ZA200401216B - Controlled drug delivery systems providing variable release rates. - Google Patents

Controlled drug delivery systems providing variable release rates.

Info

Publication number
ZA200401216B
ZA200401216B ZA200401216A ZA200401216A ZA200401216B ZA 200401216 B ZA200401216 B ZA 200401216B ZA 200401216 A ZA200401216 A ZA 200401216A ZA 200401216 A ZA200401216 A ZA 200401216A ZA 200401216 B ZA200401216 B ZA 200401216B
Authority
ZA
South Africa
Prior art keywords
drug delivery
delivery systems
release rates
controlled drug
systems providing
Prior art date
Application number
ZA200401216A
Other languages
English (en)
Inventor
John Richard Langridge
Janine Clare Collins
Wei Tian
Original Assignee
Phoqus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoqus Pharmaceuticals Ltd filed Critical Phoqus Pharmaceuticals Ltd
Publication of ZA200401216B publication Critical patent/ZA200401216B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200401216A 2001-07-19 2004-02-16 Controlled drug delivery systems providing variable release rates. ZA200401216B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0117618.9A GB0117618D0 (en) 2001-07-19 2001-07-19 Pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
ZA200401216B true ZA200401216B (en) 2005-03-17

Family

ID=9918808

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401216A ZA200401216B (en) 2001-07-19 2004-02-16 Controlled drug delivery systems providing variable release rates.

Country Status (14)

Country Link
US (1) US20060099257A1 (xx)
EP (1) EP1406597A1 (xx)
JP (2) JP2005519858A (xx)
KR (1) KR20040032857A (xx)
CN (1) CN1556697A (xx)
AU (1) AU2002317360B2 (xx)
BR (1) BR0211156A (xx)
CA (1) CA2457308A1 (xx)
GB (1) GB0117618D0 (xx)
IL (1) IL159876A0 (xx)
MX (1) MXPA04000544A (xx)
RU (1) RU2004104950A (xx)
WO (1) WO2003007919A1 (xx)
ZA (1) ZA200401216B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002333644A1 (en) 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
AR046410A1 (es) 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
EP2184058B1 (en) * 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
JP5563731B2 (ja) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
MXPA06003452A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US7390524B1 (en) 2004-05-20 2008-06-24 Advanced Cardiovascular Systems, Inc. Method for electrostatic spraying of an abluminal stent surface
NZ552841A (en) * 2004-08-04 2009-07-31 Alza Corp Controlled release dosage form comprising two layers, wherein the delay layer is substanially free of non-microencapsulated drug
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
ES2401434T3 (es) * 2004-11-19 2013-04-19 Glaxosmithkline Llc Método para dispensar de manera individualizada productos de combinación de fármacos de dosis variable para la individualización de terapias
US8017598B2 (en) * 2006-05-16 2011-09-13 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP2465500A1 (en) 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
WO2007139661A1 (en) * 2006-05-23 2007-12-06 Haley Jeffrey T Xylitol troches and methods of use
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008224844B2 (en) * 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
BRPI0908114A2 (pt) * 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd tabuleta oral de liberação controlada
TWI542338B (zh) * 2008-05-07 2016-07-21 壯生和壯生視覺關懷公司 用於活性劑之控制釋放的眼用裝置
BRPI0917206B1 (pt) 2008-07-31 2018-04-17 Clarke Mosquito Control Products, Inc. Método para a formação de uma pastilha comprimida de liberação dupla, pastilhas comprimidas e método para a fabricação de uma matriz sólida de liberação prolongada
EP2361082A1 (en) * 2008-08-14 2011-08-31 Bar-Shalom, Daniel Coated tablets with a remaining degradation surface over the time
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
LT5850B (lt) 2011-08-31 2012-07-25 Česlovas Paplauskas Vertikalaus srauto išorinis fazės apgręžiklis garso monitoriams
US8697118B2 (en) * 2011-10-18 2014-04-15 St. Teresa Medical, Inc. Stabilizers for hemostatic products
CA2859174C (en) 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
LT3019167T (lt) 2013-07-12 2021-03-25 Knopp Biosciences Llc Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
WO2015117004A1 (en) * 2014-01-31 2015-08-06 Board Of Regents, The University Of Texas System Method for preparing films
CN115645374B (zh) * 2022-12-25 2024-04-26 山东理工职业学院 一种硫酸沙丁胺醇片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
GB2253164B (en) * 1991-02-22 1994-10-05 Hoechst Uk Ltd Improvements in or relating to electrostatic coating of substrates of medicinal products
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
AU5655196A (en) * 1995-05-09 1996-11-29 Colorcon Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
PT102450B (pt) * 1999-04-13 2003-09-30 Beecham Pharm Pte Ltd Formulacao farmaceutica de libertacao modificada compreendendo amoxicilina e clavulanato de potassio e utilizacao destes compostos no fabrico de um medicamento para o tratamento de infeccoes bacterianas

Also Published As

Publication number Publication date
AU2002317360B2 (en) 2006-08-17
BR0211156A (pt) 2004-08-10
CA2457308A1 (en) 2003-01-30
US20060099257A1 (en) 2006-05-11
JP2005519858A (ja) 2005-07-07
JP2005501039A (ja) 2005-01-13
IL159876A0 (en) 2004-06-20
MXPA04000544A (es) 2005-06-06
WO2003007919A1 (en) 2003-01-30
CN1556697A (zh) 2004-12-22
EP1406597A1 (en) 2004-04-14
GB0117618D0 (en) 2001-09-12
RU2004104950A (ru) 2005-03-10
KR20040032857A (ko) 2004-04-17

Similar Documents

Publication Publication Date Title
ZA200401216B (en) Controlled drug delivery systems providing variable release rates.
MXPA03009727A (es) SISTEMA DE SUMINISTRO DE FaRMACOS DE LIBERACIoN PROLONGADA QUE CONTIENE COFARMACOS.
HUP0401438A3 (en) Drug delivery system
HUP0500795A3 (en) Gastric retention controlled drug delivery system
MX261045B (es) Sistemas de suministro de agentes beneficos.
AU2002244133A1 (en) Delivery systems for mycotechnologies, mycofiltration and mycoremediation
AU7709901A (en) Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
AU2003236947A1 (en) Modified release, multiple unit drug delivery systems
AU2002244142A1 (en) Integrated medication delivery system
IL155272A0 (en) Systems for optimized drug delivery
HK1077523A1 (en) Proliposomal drug delivery system
GB0123633D0 (en) Stent delivery system
ZA200401217B (en) Zero order controlled drug delivery system.
AU2002325034A1 (en) Stent delivery system
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2003288608A8 (en) Controlled release, multiple unit drug delivery systems
AUPR602401A0 (en) Sustained release delivery system
ZA200000610B (en) Micro-osmotic controlled drug delivery systems.
MXPA03007124A (es) Sistemas para el suministro de farmaco con objetivo anti-tumor.
GB0103877D0 (en) Novel Drug Delivery system
ZA200409726B (en) Monocompartment osmotic controlled drug delivery system.
GB0100115D0 (en) Delivery systems
AU2002222138A1 (en) Drug delivery system
AU2002210580A1 (en) Drug delivery system
AU2002246571A1 (en) Drug delivery systems